Skip to content
Home/Companies/Biotech/arGEN-X
AX

arGEN-X

Biotech·Netherlands·Exited 2017·Held 8yr

arGEN-X is a biotech company, headquartered in Netherlands.

Entry
2009
Hold
8yr
Exit
2017
Est. EV
–

Who owns arGEN-X?

arGEN-X was owned by Omnes Capital through Omnes Co-Investment (2008 vintage) from 2009 to 2017.

Hand-verified · updated 2026-04-21

Omnes Capital
Investor
Omnes Capital
Omnes Co-Investment · 2008 · Buyout

Key facts

HQNetherlands
SectorBiotech
Exit Type
–
Buyer
–
MOIC
–
Exit Year
2017

More from Omnes Co-Investment

Other portfolio companies in the same fund.

CBA
Active
TMTFrance· 2024
Arrow Global
Active
Business ServicesUK· 2023
Avania
Active
MedTechNetherlands· 2022
Ecovadis
Active
TMTFrance· 2022
Scality
Active
AI/MLUS· 2021
UTAC CERAM Millbrook
Active
Business ServicesFrance· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings